In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target
, Alexander Dierks 2, Christian H. Pfob 2, Sebastian E. Serfling 1, Andreas K. Buck 1, Theo Pelzer 5, Takahiro Higuchi 1,6, Alexander Weich 7, Ralph A. Bundschuh 2, Rudolf A. Werner 1,8,‡ and Constantin Lapa 2,*,‡Round 1
Reviewer 1 Report
Overall a very interesting work showing that an existing radiopharmaceutical therapy can be applied to additional diagnoses. Some remarks:
Was any FDG imaging done, how does that relate to the SSTR PET results?
Please improve table 1 layout under previous therapies to make it easier to see what number corresponds to what therapy.
Page 3 Scan interpretation section - Please provide further data on what "workstation" was used for evaluation of scans. If possible with software revision numbers etc.
Page 6 PRRT result section - Perhaps explain further about why there was such a difference in the number of treatment cycles, was it due to observed response, adverse effects etc?
Page 6 PRRT result section - Did the pre-treatment SUVmax or T/L values correlate in any way with outcome after PRRT?
Page 6 line 210 - Since patient immune response is reduced by haemotoxicity of PRRT, how do you motivate that the inability to survive the pneumonia is "PRRT-unrelated"?
Author Response
Please see the attachment.
Author Response File: 
Author Response.docx
Reviewer 2 Report
Good paper, solid data and well presented.
I suggest to use as acronym for PET/CT with somatostatin analogues "SRS" instead of PET, which is usually used for FDG.
My main concern is about FDG PET/CT.
Did patients performed also an FDG PET? If not, why not?
See also Martucci F, et al. Impact of 18F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2020 Jan 29;6:336. doi: 10.3389/fmed.2019.00336.
Author Response
Please see the attachment
Author Response File: Author Response.docx
